HIGHLIGHTS
- who: Ye Chen and Xingchen Peng from the Hosei University, Japan have published the paper: Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma, in the Journal: (JOURNAL)
SUMMARY
Programmed cell death ligand 1, avelumab, cost-effective, advanced or metastatic urothelial cancer, maintenance therapy COPYRIGHT A corrigendum on Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma by Xie Q, Zheng H, Chen Y, and Peng X. Public . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.